Page last updated: 2024-09-05

tbc-11251 and trimetrexate

tbc-11251 has been researched along with trimetrexate in 1 studies

Compound Research Comparison

Studies
(tbc-11251)
Trials
(tbc-11251)
Recent Studies (post-2010)
(tbc-11251)
Studies
(trimetrexate)
Trials
(trimetrexate)
Recent Studies (post-2010) (trimetrexate)
16732584225021

Protein Interaction Comparison

ProteinTaxonomytbc-11251 (IC50)trimetrexate (IC50)
Dihydrofolate reductase Mycobacterium avium0.3012
Dihydrofolate reductaseHomo sapiens (human)0.0207
Dihydrofolate reductaseLacticaseibacillus casei0.1435
Dihydrofolate reductaseSaccharomyces cerevisiae S288C0.042
Dihydrofolate reductaseEscherichia coli K-120.1798
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)0.026
Dihydrofolate reductasePneumocystis carinii0.0378
Dihydrofolate reductaseCandida albicans0.04
Dipeptidyl peptidase 4Homo sapiens (human)0.01
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)0.008
Bifunctional dihydrofolate reductase-thymidylate synthaseToxoplasma gondii0.5788
Bifunctional dihydrofolate reductase-thymidylate synthaseTrypanosoma cruzi0.0202
Dihydrofolate reductaseRattus norvegicus (Norway rat)0.0794

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for tbc-11251 and trimetrexate

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016